Neurology: Disease Deep Dive

Andrew Blumenfeld, MD, Cedars-Sinai Neurology, Los Angeles, CA, discusses the updated American Academy of Neurology and American Headache Society guideline on preventive migraine therapy, including the growing emphasis on shared decision-making, the role of CGRP-targeted therapies, and balancing efficacy with tolerability. He also examines how clinicians can assess meaningful treatment response beyond migraine frequency and explores emerging approaches to prevention, including combination therapies and novel therapeutic targets. Reference: Potrebic S, Tanveer S, Becker WJ, et al. Pharmacologic Treatment for Migraine Prevention in Adults Practice Guideline Recommendations: Report of the AAN Guidelines Subcommittee and the American Headache Society. Headache. 2026;66(9):2173-2184. doi:10.1111/head.70199

Daniel Ontaneda, MD, PhD, Cleveland Clinic, Cleveland, OH, explains why traditional labels such as relapsing-remitting, secondary progressive, and primary progressive multiple sclerosis (MS) may not fully reflect the underlying biology of the disease and why a more dynamic framework could better capture how MS changes over time.

Hubert Fernandez, MD, Cleveland Clinic, Cleveland, OH, discusses findings from the TEMPO trials evaluating tavapadon, a selective dopamine D1/D5 receptor partial agonist, as monotherapy in early Parkinson disease and as an adjunct to levodopa in patients with motor fluctuations. He examines efficacy, tolerability, adverse events, and where tavapadon could fit within the evolving Parkinson disease treatment landscape.

In this episode, Patrick J. Strollo Jr, MD, FACP, FCCP, FAASM, of the University of Pittsburgh Department of Medicine, Pittsburgh, PA, discusses the data from the phase 3 SynAIRgy clinical trial for AD109, an investigational once-nightly oral treatment targeting neuromuscular dysfunction in obstructive sleep apnea, and its potential role in a more personalized approach to OSA care.

This episode explores the real-world implementation of the Davos Alzheimer’s Collaborative Healthcare System Preparedness (DAC-SP) US Early Detection Program at Virtua Health, examining outcomes in identifying cognitive impairment, streamlining referrals, and supporting efficient use of clinical resources. Elyse Perweiler, RN, MPP, Professor, Rowan–Virtua School of Osteopathic Medicine, Stratford, NJ, and Tim MacLeod, PhD, Executive Director, Healthcare System Preparedness Program, DAC, Toronto, Ontario, Canada, return for part 2 of this 3 part series.